[
  {
    "ts": null,
    "headline": "B of A Securities Maintains Pfizer (PFE) Neutral Recommendation",
    "summary": "B of A Securities Maintains Pfizer (PFE) Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=adb34f731f0bf5fa4e2004031b8b18a23ad5903fa870b233aed1ea1387d4fe0c",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765814923,
      "headline": "B of A Securities Maintains Pfizer (PFE) Neutral Recommendation",
      "id": 137794014,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=adb34f731f0bf5fa4e2004031b8b18a23ad5903fa870b233aed1ea1387d4fe0c"
    }
  },
  {
    "ts": null,
    "headline": "BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?",
    "summary": "BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.",
    "url": "https://finnhub.io/api/news?id=1d4a90b0200d0f97c62ae38bef46dd9a306144d0cf979a0704ceb7ef8d7748a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765809120,
      "headline": "BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?",
      "id": 137792667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.",
      "url": "https://finnhub.io/api/news?id=1d4a90b0200d0f97c62ae38bef46dd9a306144d0cf979a0704ceb7ef8d7748a0"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=32767a126385927b17c3d08487918e698caea3c4273887d92f5378a61a14ea20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765807203,
      "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
      "id": 137795438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=32767a126385927b17c3d08487918e698caea3c4273887d92f5378a61a14ea20"
    }
  },
  {
    "ts": null,
    "headline": "GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients",
    "summary": "DSMB Ends Comparator Arm; Trial Proceeds Exclusively With GEO-CM04S1 Following mRNA Vaccine's Failure to Meet Primary Endpoint Phase 2 Data Reinforce GEO-CM04S1 as an Important Next-generation Vaccine Candidate for the 40 Million U.S. and 400 Million...",
    "url": "https://finnhub.io/api/news?id=526bc1e4003351dd3d93596ade65765b7a0d2c1480de7e051ac2964156969490",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765807200,
      "headline": "GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients",
      "id": 137792584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "DSMB Ends Comparator Arm; Trial Proceeds Exclusively With GEO-CM04S1 Following mRNA Vaccine's Failure to Meet Primary Endpoint Phase 2 Data Reinforce GEO-CM04S1 as an Important Next-generation Vaccine Candidate for the 40 Million U.S. and 400 Million...",
      "url": "https://finnhub.io/api/news?id=526bc1e4003351dd3d93596ade65765b7a0d2c1480de7e051ac2964156969490"
    }
  },
  {
    "ts": null,
    "headline": "Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer",
    "summary": "A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat",
    "url": "https://finnhub.io/api/news?id=54b17086d55d7de90b5c40c22d8644ba5b35bf272ebd59b8f9d8c5637cb38cec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765803600,
      "headline": "Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer",
      "id": 137792585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat",
      "url": "https://finnhub.io/api/news?id=54b17086d55d7de90b5c40c22d8644ba5b35bf272ebd59b8f9d8c5637cb38cec"
    }
  },
  {
    "ts": null,
    "headline": "Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial",
    "summary": "IDEAYA Biosciences recently completed full enrollment of 435 patients in its registration-enabling Phase 2/3 OptimUM-02 trial testing oral PKC inhibitor darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, while also advancing IDE034 and IDE574 into early-stage clinical development. This milestone underscores IDEAYA’s push to convert promising early uveal melanoma data and multiple FDA designations for darovasertib into a potential accelerated...",
    "url": "https://finnhub.io/api/news?id=073f61f44715ae93f7100c375cf3d8258683e5d45dae26c61edf27a253c6461f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765757903,
      "headline": "Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial",
      "id": 137792586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "IDEAYA Biosciences recently completed full enrollment of 435 patients in its registration-enabling Phase 2/3 OptimUM-02 trial testing oral PKC inhibitor darovasertib plus Pfizer’s crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, while also advancing IDE034 and IDE574 into early-stage clinical development. This milestone underscores IDEAYA’s push to convert promising early uveal melanoma data and multiple FDA designations for darovasertib into a potential accelerated...",
      "url": "https://finnhub.io/api/news?id=073f61f44715ae93f7100c375cf3d8258683e5d45dae26c61edf27a253c6461f"
    }
  }
]